Michael Nohaile
Vermögen: 445 845 $ am 31.05.2026
Vermögen: 445 845 $ am 31.05.2026
Michael Nohaile is currently Chief Executive Officer at Prellis Biologics, Inc. since 2022 and Independent Director at Fulgent Genetics, Inc. since 2022.
Former roles include Director at Genoptix, Inc., Chief Scientific Officer at Generate Biomedicines, Inc. from 2021 to 2022, Senior VP-Strategy, Commercialization & Innovation at Amgen, Inc. from 2012 to 2021, Global Head-Molecular Diagnostics at Novartis AG from 2008 to 2012, General Manager-Molecular Diagnostics Business at Novartis Corp.
from 2007 to 2012, and Partner at McKinsey & Co., Inc. from 2000 to 2007.
Education includes undergraduate studies at Massachusetts Institute of Technology and a doctorate from the University of California, Berkeley.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FULGENT GENETICS, INC. 0,08 % | 14.05.2026 | 24.578 ( 0,08 % ) | 445 845 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FULGENT GENETICS, INC. | Direktor/Vorstandsmitglied | 01.08.2022 |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Develops novel technology to bio print vascularized human tissues | Vorstandsvorsitzender | 11.08.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| GENERATE BIOMEDICINES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2022 |
| AMGEN INC. | Corporate Officer/Principal | 01.02.2021 |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Corporate Officer/Principal | 01.11.2012 |
| NOVARTIS AG | Corporate Officer/Principal | 01.11.2012 |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Corporate Officer/Principal | 01.01.2007 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Genoptix, Inc.
Genoptix, Inc. Medical SpecialtiesHealth Technology Provides personalized medicine services | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmacitical products | Health Technology |
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulgent Genetics, Inc.
Fulgent Genetics, Inc. Medical/Nursing ServicesHealth Services Provides genetic diagnostics services | Health Services |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Develops novel technology to bio print vascularized human tissues | Health Technology |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Operates as a clinical-stage generative biology company that provides biotechnology and drug design & development services | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen